Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
23.32
+0.28 (1.22%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Structure Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Structure Therapeutics stock have an average target of 80.71, with a low estimate of 50 and a high estimate of 118. The average target predicts an increase of 246.10% from the current stock price of 23.32.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Structure Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 6 | 5 | 5 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 | Strong Buy | Maintains | $80 | +243.05% | Apr 22, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $91 → $87 | Buy | Maintains | $91 → $87 | +273.07% | Feb 28, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 28, 2025 |
| Stifel | Stifel | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +114.41% | Jan 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +243.05% | Dec 20, 2024 |
Financial Forecast
Revenue This Year
n/a
from 358.62M
Revenue Next Year
n/a
EPS This Year
-1.09
from -2.33
EPS Next Year
-1.50
from -1.09
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.86 | -1.08 | -1.24 | ||
| Avg | -1.09 | -1.50 | -1.58 | ||
| Low | -1.53 | -1.91 | -1.87 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.